The proposed amendments to the patented medicines regulations by the Patented Medicine Prices Review Board could have a big impact on both the group insurance and pharmaceutical industry. “The CLHIA is very supportive of PMPRB adjustments that may be coming,” said Joan Weir, director of health and disability policy at the Canadian Life and Health […]
Innovative technology to monitor glucose levels for patients with diabetes offers improved health outcomes, reduced absenteeism and improved productivity, said Rick Siemens, certified diabetes educator pharmacist, during a webinar in June hosted by Benefits Canada and sponsored by Dexcom. The roles of pharmacists in Canada are evolving. Siemens said he spends most of his time […]
Approximately 10 per cent of Canadians live with diabetes and one in 300 children live with Type 1 diabetes, according to Dr. Angelo Simone, a paediatric endocrinologist at Trillium Health Partners, during a webinar hosted by Benefits Canada and sponsored by Abbott in April. As a parent caring for two children living with Type 1 […]
With Canadian biologic drug sales growing at a rate of 13 per cent annually over the last 10 years, plan sponsors are looking for ways to manage the related costs — and the introduction of biosimilars may help. At a recent Pfizer-sponsored webinar hosted by Benefits Canada, “Evidence to Policy — Biosimilar Transitioning in Canada,” two […]
A recent Telus Health comparison of a drug’s cost effectiveness when calculated from the private versus the public-payer perspective demonstrated clearly that the private-payer perspective matters when assessing the value of a medication, explained Dr Nina Lathia, pharmacist, and health economist, at Benefits Canada’s Face to Face Drug Plan Management Forum on Dec. 9, 2020. […]